Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia

Rauch Bernhard

首页> 外文期刊>European journal of preventive cardiology >Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia

【24h】

Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia

机译：Rivaroxaban加阿司匹林（双途径抑制）的成本效益预防心血管疾病患者缺血事件：在Covid-19 Pandemia背景下的高级预防药物的优化

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of preventive cardiology》 |2020年第13期|共3页
作者
Rauch Bernhard;
展开▼
作者单位

IHF Inst Herzinfarktforsch Ludwigshafen Bremserstr 79 Haus M D-67063 Ludwigshafen Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study [J] . Petersohn Svenja, Pouwels Xavier, Ramaekers Bram, European journal of preventive cardiology . 2020,第13期

机译：Rivaroxaban Plus Aspirin用于预防心血管疾病患者的缺血事件：一种成本效益研究
2. Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases [J] . Lee Mei-Chuan, Liao Chia-Te, Toh Han Siong, Cardiovascular drugs and therapy . 2021,第3期

机译：Rivaroxaban Plus Aspirin对慢性心血管疾病患者二次预防中的rivaroxaban Plus阿司匹林与阿司匹林的成本效果分析
3. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. [J] . Chen J, Bhatt DL, Dunn ES, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2009,第6期

机译：氯吡格雷加阿司匹林与单独使用阿司匹林在心血管事件二级预防中的成本效益：CHARISMA试验的结果。
4. Smartphone-Based Self-Empowerment App on Secondary Prevention of Patients with Cardiovascular Disease [C] . Yisi Liu, Jingyi Chen, Karen V. Lamb, MEDINFO . 2019

机译：基于智能手机的自我赋权应用程序二次预防心血管疾病患者
5. Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events [O] . Laurence M. Djatche, Stefan Varga, Robert D. Lieberthal 2018

机译：阿司匹林依从性对心血管事件的二级预防的成本效益
6. Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia [O] . Bernhard Rauch 2020

机译：Rivaroxaban Plus Aspirin（双途径抑制）的成本效益预防心血管疾病患者缺血事件：在Covid-19 Pandemia背景下的二级预防药物的优化

Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia

著录项

相似文献

相关主题

期刊订阅